Psyllium reduces inulin-induced colonic gas production in IBS: MRI and fermentation studies.

David Gunn, Zainab Abbas, Hannah C Harris, Giles Major, Caroline Hoad, Penny Gowland, Luca Marciani, Samantha K Gill, Fred J Warren, Megan Rossi, Jose Maria Remes-Troche, Kevin Whelan, Robin C Spiller

Journal: Gut 2022;71(5):919-927

PMID: 34353864

Abstract

OBJECTIVE

Health-promoting dietary fibre including inulin often triggers gastrointestinal symptoms in patients with IBS, limiting their intake. Our aim was to test if coadministering psyllium with inulin would reduce gas production.

DESIGN

A randomised, four-period, four-treatment, placebo-controlled, crossover trial in 19 patients with IBS. Subjects ingested a 500 mL test drink containing either inulin 20 g, psyllium 20 g, inulin 20 g+ psyllium 20 g or dextrose 20 g (placebo). Breath hydrogen was measured every 30 min with MRI scans hourly for 6 hours. Faecal samples from a subset of the patients with IBS were tested using an fermentation model. Primary endpoint was colonic gas assessed by MRI.

RESULTS

Colonic gas rose steadily from 0 to 6 hours, with inulin causing the greatest rise, median (IQR) AUC 3145 (848-6502) mL·min. This was significantly reduced with inulin and psyllium coadministration to 618 (62-2345) mL·min (p=0.02), not significantly different from placebo. Colonic volumes AUC were significantly larger than placebo for both inulin (p=0.002) and inulin and psyllium coadministration (p=0.005). Breath hydrogen rose significantly from 120 min after inulin but not psyllium; coadministration of psyllium with inulin delayed and reduced the maximum increase, AUC from 7230 (3255-17910) ppm·hour to 1035 (360-4320) ppm·hour, p=0.007.Fermentation produced more gas with inulin than psyllium. Combining psyllium with inulin did not reduce gas production.

CONCLUSIONS

Psyllium reduced inulin-related gas production in patients with IBS but does not directly inhibit fermentation. Whether coadministration with psyllium increases the tolerability of prebiotics in IBS warrants further study.

TRIAL REGISTRATION NUMBER

NCT03265002.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Address: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.; Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK.; Food, Innovation and Health, Quadram Institute Bioscience, Norwich, UK.; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.; Sir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK.; Department of Nutritional Sciences, King's College London, London, UK.; Medical Biological Research Institute, Veracruzana University, Veracruz, Mexico.; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK [email protected].; Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.